Paratek Pharmaceuticals Inc PRTK:NASDAQ

Last Price$1.96NASDAQ Closing Price as of 4:00PM ET 7/01/22

Today's Change+0.03(1.55%)
Bid (Size)$1.90 (5)
Ask (Size)$2.26 (2)
Day Low / High$1.89 - 1.98
Volume520.3 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022


Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $1.96
Change: +0.03 (1.55%)
Volume: 520.3 K
4:00PM ET 7/01/2022

Gamida Cell Ltd ( NASDAQ )

Price: $1.74
Change: -0.03 (1.69%)
Volume: 323.7 K
4:00PM ET 7/01/2022

Dare Bioscience Inc ( NASDAQ )

Price: $1.19
Change: -0.04 (3.25%)
Volume: 773.5 K
4:00PM ET 7/01/2022

OncoCyte Corp ( NASDAQ )

Price: $0.85
Change: -0.05 (5.30%)
Volume: 446.1 K
4:00PM ET 7/01/2022

PDS Biotechnology Corp ( NASDAQ )

Price: $3.69
Change: +0.04 (1.10%)
Volume: 341.9 K
4:00PM ET 7/01/2022

Read more news Recent News

Paratek Pharmaceuticals Wins FDA Fast Track for Pulmonary Antibiotic
4:28PM ET 6/21/2022 MT Newswires

Paratek Pharmaceuticals (PRTK) on Tuesday said it had received the FDA's expedited Fast Track designation for its NUZYRA (omadacycline) antibiotic treating...

-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Posts Q1 Revenue $24.9M, vs. Street Est of $27.2M
4:57PM ET 5/04/2022 MT Newswires


-- Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Posts Q1 Revenue $24.9M, vs. Street Est of $27.2M
4:57PM ET 5/04/2022 MT Newswires


--BTIG Research Adjusts Paratek Pharmaceuticals Price Target to $30 From $34, Maintains Buy Rating
12:11PM ET 4/11/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionParatek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA. View company web site for more details
Address75 Park Plaza
Boston, Massachusetts 02116-3934
Number of Employees104
Recent SEC Filing06/09/20228-K
Chief Executive Officer & DirectorEvan Loh
President & Chief Commercial OfficerAdam Woodrow
VP, Chief Financial & Accounting OfficerSarah Higgins
Vice President-Information TechnologyRaj Padmanabhan

Company Highlights

Price Open$1.92
Previous Close$1.93
52 Week Range$1.60 - 7.27
Market Capitalization$106.8 M
Shares Outstanding54.5 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.16
Beta vs. S&P 500N/A
Revenue$17.1 M
Net Profit Margin-42.38%
Return on Equity49.74%

Analyst Ratings as of 05/20/2022

Consensus RecommendationConsensus Icon
Powered by Factset